Who is sponsoring NCT00354510?

NCT00354510 is sponsored by GlaxoSmithKline.

What condition does NCT00354510 study?

NCT00354510 studies Atopic Dermatitis, Dermatitis, Atopic.

What drugs are being tested in NCT00354510?

Interventions: GW842470X cream.

What is the status of NCT00354510?

NCT00354510 is currently COMPLETED.

Last reviewed 2012-05-31 · How we verify

Randomised, Double-blind, Placebo-controlled Study of Topical GW842470X Formulation in Adults With Moderate Atopic Dermatitis

NCT00354510 Phase 2 COMPLETED

The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of disease severity and to investigate the safety of and tolerability of 3% GW842470X cream on diseased skin of adult patients.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	COMPLETED
Enrolment	190
Start date	2006-03

Conditions

Atopic Dermatitis
Dermatitis, Atopic

Interventions

GW842470X cream

Primary outcomes

Clinical efficacy of 3% GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI).

Countries

Germany, Netherlands